research Tacrolimus Ointment: Summarizing Two Decades of Experience in Off-Label Use. Use in Rosacea, Seborrheic Dermatitis, Papulosquamous Dermatoses, Lupus Erythematosus, Eczematous Dermatoses, Alopecia, and Other Diseases
Tacrolimus ointment, a topical calcineurin inhibitor, has shown promise in treating a variety of chronic inflammatory and autoimmune dermatoses beyond its approved use for atopic dermatitis. Its immunosuppressive and anti-inflammatory properties, along with its safety on delicate skin areas, have led to its off-label use in conditions such as rosacea, seborrheic dermatitis, papulosquamous dermatoses (including psoriasis and lichen planus), lupus erythematosus, and various eczematous dermatoses. The review highlights its potential in treating alopecia and other less common skin diseases, suggesting that expanding its indications could enhance dermatological practice. The analysis of clinical trials and observational studies supports further research into its broader applications.
